PROBLEM TO BE SOLVED: To provide a novel eIF2α phosphorylation accelerator.SOLUTION: According to the present invention, there is provided a compound represented by the formula (4) or a bupranolol derivative (1-phenoxy-3-alkylamino-propane-2-ol derivative). Here, phosphorylation of eIF2α is promoted through a path different from that of PERK and GCN2. There is also provided a therapeutic agent for the prevention or treatment of metabolism, cranial nerve, cancer, immune disorders. [X and Y each independently represent H, a halogen atom, a C1-4 alkyloxy group, etc., or X and Y together form a 1,2-di-oxyethylene group, etc.； Z represents H, a halogen atom, a C1-4 alkyloxy group, etc.]SELECTED DRAWING: None【課題】新規なｅＩＦ２αのリン酸化促進剤の提供。【解決手段】式（４）で表される化合物又はブプラノロール誘導体（１－フェノキシ－３－アルキルアミノ－プロパン－２－オール誘導体）。ＰＥＲＫとＧＣＮ２の経路とは異なる経路でｅＩＦ２αのリン酸化を促進。新たな代謝、脳神経、癌、免疫疾患の予防又は治療用薬剤。[Ｘ及びＹは夫々独立にＨ、ハロゲン原子、Ｃ１～４のアルキルオキシ基等、或いはＸ及びＹが一緒になって１，２－ジオキシエチレン基等；ＺはＨ、ハロゲン原子、Ｃ１～４のアルキルオキシ基等]の【選択図】なし
